The World Obesity Federation projects that over 50% of the global population will become obese or overweight in the next 10-15 years if the current trends in diet and lifestyle continue. As such, this places a major burden on healthcare providers, especially nurses involved in providing advice related to weight loss and managing obesity among patients. It is, therefore, important for a nurse in Texas to stay up to date with the emerging solutions and treatments to this growing epidemic.
Weight loss drugs
Losing weight is difficult for many people. While diet and exercise are important components of weight loss, some people feel that they are not enough to achieve their desired body goals. This is why many people turn to the use of drugs or supplements that can help them lose weight.
To ensure people remain safe, the U.S. Food and Drug Administration (FDA) approved drugs such as semaglutide (brand names Ozempic and Wegovy) and tirzepatide (brand name Mounjaro) for professionals in the healthcare business to administer to their diabetic patients.
However, it should be noted that Ozempic and Mounjaro are not FDA-approved for weight loss. They are only approved for use in managing diabetes. While Wegovy is FDA-approved to treat obesity, it is not approved for people whose body mass index is less 30 kilograms per meter squared.
Legal challenges
These drugs can also cause severe side effects. For instance, semaglutide can cause medullary thyroid carcinoma, severe allergic reactions, acute kidney injury, gastrointestinal problems, pancreatitis and more. If a healthcare practitioner fails to take these into consideration when administering these drugs to the patient, they could face a medical malpractice lawsuit.
Weight loss drugs can an important part of managing obesity in some patients, but it is important for healthcare providers to understand all the risks associated with prescribing them and properly consider the different options available beforehand.